234 related articles for article (PubMed ID: 18341241)
1. Patient profiles in psoriatic disease: a case-based approach.
Wiatrowski M; Furfaro N
Dermatol Nurs; 2007 Oct; Suppl():5-19; quiz 20-1. PubMed ID: 18341241
[TBL] [Abstract][Full Text] [Related]
2. Infliximab treatment in psoriatic arthritis: our experience.
Rioda WT; Adorni G
Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
[TBL] [Abstract][Full Text] [Related]
3. [Biological agents in treatment of psoriatic arthritis].
Lewicki M; Dutkiewicz B; Widuchowska M; Kucharz EJ
Pol Merkur Lekarski; 2008 Jul; 25(145):97-100. PubMed ID: 18839626
[TBL] [Abstract][Full Text] [Related]
4. Biologic therapy of psoriatic arthritis.
Gladman DD
Reumatismo; 2007; 59 Suppl 1():85-7. PubMed ID: 17828353
[TBL] [Abstract][Full Text] [Related]
5. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
Fénix-Caballero S; Alegre-del Rey EJ; Castaño-Lara R; Puigventós-Latorre F; Borrero-Rubio JM; López-Vallejo JF
J Clin Pharm Ther; 2013 Aug; 38(4):286-93. PubMed ID: 23590560
[TBL] [Abstract][Full Text] [Related]
6. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
Paul C; Solignac M
Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
[No Abstract] [Full Text] [Related]
7. Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator.
Migliore A; Bizzi E; Broccoli S; Laganà B
Clin Rheumatol; 2012 Jan; 31(1):193-4. PubMed ID: 22005889
[No Abstract] [Full Text] [Related]
8. Errors noted in: re: Migliore A, Bizzi E, Broccoli S Laganà (2011). Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Published on line June 21st 2011.
O'Regan C
Clin Rheumatol; 2011 Dec; 30(12):1647-8. PubMed ID: 21938451
[No Abstract] [Full Text] [Related]
9. [Biological treatment of psoriasis and psoriatic arthritis].
Kragballe K; Deleuran B
Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
[TBL] [Abstract][Full Text] [Related]
10. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
11. [Anti-TNF alpha in the treatment of psoriatic arthritis].
Claudepierre P; Wendling D; Cohen JD
Presse Med; 2006 Apr; 35(4 Pt 2):647-55. PubMed ID: 16614610
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
13. Psoriatic arthritis patients doing better on infliximab than etanercept.
Smith N; Gadsby K; Deighton C
Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216
[No Abstract] [Full Text] [Related]
14. [Novel biologics in treatment of psoriatic arthritis].
ZHOU J; ZHENG M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):404-8. PubMed ID: 19693980
[TBL] [Abstract][Full Text] [Related]
15. Psoriatic arthritis.
Goupille P
Joint Bone Spine; 2005 Dec; 72(6):466-70. PubMed ID: 16310398
[TBL] [Abstract][Full Text] [Related]
16. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
17. No evidence-based practice by biased information from systematic reviews: the case of etanercept and infliximab for the treatment of psoriatic arthritis.
Corrao S; Puleo A; Pistone G; Calvo L; Scaglione R; Licata G
Clin Exp Rheumatol; 2008; 26(1):164; author reply 165. PubMed ID: 18328174
[No Abstract] [Full Text] [Related]
18. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
19. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
20. Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator.
Migliore A; Bizzi E; Broccoli S; Laganà B
Clin Rheumatol; 2012 Jan; 31(1):133-7. PubMed ID: 21701796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
